Global Synovial Sarcoma Treatment Market - 2024-2031

Global Synovial Sarcoma Treatment Market - 2024-2031

The global synovial sarcoma treatment market reached US$ 832.47 million in 2023 and is expected to reach US$ 1646.61 million by 2031 growing with a CAGR of 8.9% during the forecast period 2024-2031.

Synovial sarcoma is a rare type of soft tissue sarcoma that develops most frequently in tissues deep within the arms, legs, and feet. Also called synovial cell sarcoma, these malignant (cancerous) tumors got their name from similarities to cells in synovial joints—common joints such as the elbows and hips.

Synovial sarcoma accounts for 5% to 10% of soft-tissue cancers. The treatment for synovial sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The specific treatment plan will depend on the size, location, and stage of the tumor, as well as the patient's overall health and personal preferences.

Market Dynamics: Drivers

Rising Research and Developments & Increasing FDA Approvals for Synovial Sarcoma

The demand for the global synovial sarcoma treatment market is driven by multiple factors. One of the key factors is the market has grown significantly due to various recent research and developments. Synovial sarcoma occurs most commonly in the younger patients under 30 years of age. While overall comprising about 8% of all soft tissue sarcomas, it accounts for 15-20% of the cases in adolescents and young adults.

For instance, in December 2022, Adaptimmune Therapeutics announced the initiation of biologics license application (BLA) submission for Afami-cel which is their first-generation engineered TCR T-cell therapy targeting MAGE-A4 for the treatment of synovial sarcoma. The biologics license submission for afami-cel is supported by positive clinical data from Adapt Immune's SPEARHEAD-1 clinical trial in patients with advanced synovial sarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.

Moreover, increasing FDA approvals for the synovial sarcoma treatment would propel this market growth. For instance, in December 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft tissue sarcoma (ASPS). The efficacy of atezolizumab 15 mg/kg given once every 21 days was tested in pediatric patients.

Also, in March 2022, C4 Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 for the treatment of soft tissue sarcoma.

Restraints

Factors such as the high cost of the treatment, side effects associated with the immunotherapy, lack of awareness & diagnosis, limited treatment options, and stringent regulatory requirements & reimbursement issues, are expected to hamper the market.

Segment Analysis

The global synovial sarcoma treatment market is segmented based on treatment, end users, and region.

The immunotherapy segment accounted for approximately 45.3% of the global synovial sarcoma treatment market share

The immunotherapy segment is expected to hold the largest market share over the forecast period. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.

The rising number of clinical trials for immunotherapy and the increasing approvals of immunotherapy drugs have contributed to the growing demand for synovial sarcoma treatment. For instance, in February 2024, Immunotherapy before surgery leads to promising long-term survival in sarcoma patients. MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas.

Similarly, in March 2024, an immunotherapy clinical trial showed promise for treating rare sarcomas. Now, a phase 2 clinical trial testing an experimental cell therapy called afamitresgene autoleucel (afami-cel) found that it significantly shrank sarcoma tumors in more than one-third of patients.

Also, in October 2023, the Clinical Cancer Research publication stated that the immunotherapy with TBI-1301 to target NY-ESO-1-positive tumor cells demonstrated promising results for the treatment of advanced or recurrent synovial sarcoma.

Geographical Analysis

North America accounted for approximately 42.3% of the global synovial sarcoma market share

North America region is expected to hold the largest market share over the forecast period owing to factors such as the rising prevalence of soft tissue sarcoma, increasing research and developments, and technological advancements in synovial sarcoma treatment.

According to the American Cancer Society, the estimation for soft tissue sarcomas in the United States for 2023 is around 13,400 new soft tissue sarcomas that will be diagnosed (7,400 in males and 6,000 in females) and about 5,140 people are expected to die of soft tissue sarcomas. The increasing number of synovial sarcoma diagnoses creates a pressing demand for effective treatments in this region.

In addition, a well-advanced healthcare system, rising clinical trials, and research studies in the treatment of synovial sarcoma would propel this market growth. For instance, in May 2023, Immatics provided an interim update on cohort A of its Phase Ib dose-expansion trial evaluating its leading T-cell receptor-based therapy (TCR-T) candidate IMA203. The best responders to IMA203 in the small cohort were patients with cutaneous and uveal melanoma, synovial sarcoma, and platinum-resistant ovarian cancer.

Also, in June 2023, Replay Holdings LLC and The University of Texas MD Anderson Cancer Center announced that the FDA has cleared the IND application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

Market Segmentation

By Treatment
• Anti-angiogenesis Drugs
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By End Users
• Hospitals
• Oncology centers
• Ambulatory Surgical centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the synovial sarcoma market include Pfizer Inc., Dr. Reddy's Laboratories, Hetero Healthcare, Teva Pharmaceuticals, Sterling Biotech Ltd., Baxter International, Janssen Pharmaceuticals, Concord Biotech Ltd., Novartis AG, Taiho Pharmaceuticals among others.

Key Developments

In February 2024, the FDA accepted for priority review the biologics license application (BLA) seeking the approval of afamitresgene autoleucel (afami-cel), an investigational engineered T-cell therapy, for the treatment of patients with advanced synovial sarcoma.

In December 2023, the grand opening of HKSH’s proton therapy center marks a significant advancement in precision cancer treatment in Hong Kong. All six pediatric cancer cases were referred by the Hong Kong Children's Hospital. These pediatric cases involve neuroblastoma, synovial sarcoma, maxillary sinus sarcoma, maxillary sinus carcinoma, and craniopharyngioma.

In October 2023, Takara Bio Inc., announced that the results from the clinical trial of NY-ESO-1・siTCRTM gene therapy for patients with advanced or recurrent synovial sarcoma were published in Clinical Cancer Research Online, a journal of the American Association for Cancer Research (AACR).

In February 2023, Medsafe approved the use of YONDELIS (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Why Purchase the Report?
• To visualize the global synovial sarcoma treatment market segmentation based on the treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global synovial sarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global synovial sarcoma treatment market report would provide approximately 54 tables, 47 figures, and 182 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies